Encompass Health Corp EHC
We take great care to ensure that the data presented and summarized in this overview for Encompass Health Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EHC
View all-
Vanguard Group Inc Valley Forge, PA10.2MShares$1.02 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY9.05MShares$905 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$689 Million0.11% of portfolio
-
Invesco Ltd. Atlanta, GA5.09MShares$509 Million0.09% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.89MShares$389 Million0.91% of portfolio
-
State Street Corp Boston, MA3MShares$300 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.23MShares$223 Million0.02% of portfolio
-
Td Asset Management Inc1.94MShares$194 Million0.16% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.82MShares$182 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.65MShares$165 Million0.01% of portfolio
Latest Institutional Activity in EHC
Top Purchases
Top Sells
About EHC
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment provides home health and hospice services primarily in the Southeast and Texas. Its home health services include a range of Medicare-certified home nursing services to adult patients in need of care comprising skilled nursing, medical social work, and home health aide services, as well as physical, occupational, speech therapy, and others. This segment's hospice services comprise in-home services to terminally ill patients and their families. As of June 1, 2022, it operated 149 hospitals, 252 home health locations, and 99 hospice locations in 42 states and Puerto Rico. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. Encompass Health Corporation was founded in 1983 and is based in Birmingham, Alabama.
Insider Transactions at EHC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 17
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
362
+2.87%
|
$35,114
$97.53 P/Share
|
Oct 17
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+6.03%
|
$27,451
$97.63 P/Share
|
Oct 15
2024
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.18%
|
-
|
Oct 15
2024
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.17%
|
-
|
Oct 15
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.18%
|
-
|
Oct 15
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.13%
|
-
|
Oct 15
2024
|
Leslye G Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
81
+0.18%
|
-
|
Oct 15
2024
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.18%
|
-
|
Oct 15
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.15%
|
-
|
Oct 15
2024
|
Joan E Herman Director |
BUY
Grant, award, or other acquisition
|
Direct |
81
+0.18%
|
-
|
Oct 15
2024
|
Greg D Carmichael Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.14%
|
-
|
Aug 13
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,260
-4.13%
|
$1,054,360
$86.68 P/Share
|
Aug 13
2024
|
Douglas E Coltharp EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,260
+7.63%
|
$429,100
$35.83 P/Share
|
Jul 16
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
426
+3.47%
|
$36,636
$86.63 P/Share
|
Jul 16
2024
|
Edward M Christie Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
334
+7.5%
|
$28,724
$86.8 P/Share
|
Jul 15
2024
|
Greg D Carmichael Director |
BUY
Small Acquisition
|
Direct |
7
+0.04%
|
$602
$86.89 P/Share
|
Jul 15
2024
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.18%
|
-
|
Jul 15
2024
|
Terrance Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.18%
|
-
|
Jul 15
2024
|
Kevin J. O'Connor Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.15%
|
-
|
Jul 15
2024
|
Christopher R Reidy Director |
BUY
Grant, award, or other acquisition
|
Direct |
16
+0.14%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 186K shares |
---|---|
Exercise of conversion of derivative security | 88.4K shares |
Small Acquisition | 14 shares |
Open market or private purchase | 2K shares |
Payment of exercise price or tax liability | 62K shares |
---|---|
Open market or private sale | 93K shares |